Investors and Media Overview

Enzon to Release Fourth Quarter 2010 Earnings on Thursday, February 17, 2011; Conference Call and Webcast to Follow

Feb 10, 2011

PISCATAWAY, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it will report its financial results for the quarter ended December 31, 2010, on Thursday, February 17, 2011 at 4:00 pm Eastern Time (ET). The release will be followed by a live conference call, which will begin at 5:00 pm Eastern Time (ET) on Thursday, February 17, 2011.

All interested parties may access the call by using the following information:

Domestic Dial-In Number:   (877) 561 - 2748
International Dial-In Number: (720) 545 - 0044
Access Code: Enzon

The call will also be available via live audio webcast on the Enzon website, by going to the ‘Calendar of Events' page in the ‘Investors' section. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Thursday, February 17, 2011 at approximately 8:00 pm Eastern Time (ET) and end on Thursday, February 24, 2011 at approximately 11:59 pm Eastern Time (ET). It may be accessed using the following information:

Domestic Dial-In Number:   (800) 642 - 1687
International Dial-In Number: (706) 645 - 9291
Conference ID: 43332453

About Enzon

Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs. Enzon's drug-development programs utilize two platforms - Customized PEGylation Linker Technology (Customized Linker Technology®) and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon currently has four product candidates in clinical development and multiple novel LNA targets in preclinical research. Enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary Customized Linker Technology. Further information about Enzon and this press release can be found on the Company's web site at

Argot Partners
Andrea Rabney, 212-600-1902

Source: Enzon Pharmaceuticals, Inc.

News Provided by Acquire Media